Lima Viviane Dias, Kerr Thomas, Wood Evan, Kozai Tsubasa, Salters Kate A, Hogg Robert S, Montaner Julio S G
a British Columbia Centre for Excellence in HIV/AIDS , Vancouver , BC , Canada.
AIDS Care. 2014 Jan;26(1):123-9. doi: 10.1080/09540121.2013.804900. Epub 2013 Jun 14.
The effectiveness of highly active antiretroviral therapy (HAART) in preventing disease progression can be negatively influenced by the high prevalence of substance use among patients. Here, we quantify the effect of history of injection drug use and alcoholism on virologic and immunologic response to HAART. Clinical and survey data, collected at the start of HAART and at the interview date, were based on the study Longitudinal Investigations into Supportive and Ancillary Health Services (LISA) in British Columbia, Canada. Substance use was a three-level categorical variable, combining information on history of alcohol dependence and of injection drug use, defined as: no history of alcohol and injection drug use; history of alcohol or injection drug use; and history of both alcohol and injection drug use. Virologic response (pVL) was defined by ≥ 2 log10 copy/mL drop in a viral load. Immunologic response was defined as an increase in CD4 cell count percent of ≥ 100%. We used cumulative logit modeling for ordinal responses to address our objective. Of the 537 HIV-infected patients, 112 (21%) were characterized as having a history of both alcohol and injection drug use, 173 (32%) were nonadherent (<95%), 196 (36%) had a CD4⁺/pVL⁺ (Best) response, 180 (34%) a CD4⁺/pVL⁻ or a CD4⁻ /pVL⁺ (Incomplete) response, and 161 (30%) a CD4⁻ /pVL⁻ (Worst) response. For individuals with history of both alcohol and injection drug use, the estimated probability of non-adherence was 0.61, and (0.15, 0.25, 0.60) of Best, Incomplete and Worse responses, respectively. Screening and detection of substance dependence will identify individuals at high-risk for nonadherence and ideally prevent their HIV disease from progressing to advanced stages where HIV disease can become difficult to manage.
高效抗逆转录病毒疗法(HAART)在预防疾病进展方面的有效性可能会受到患者中药物使用高流行率的负面影响。在此,我们量化注射吸毒史和酗酒对HAART病毒学和免疫反应的影响。在HAART开始时和访谈日期收集的临床和调查数据基于加拿大不列颠哥伦比亚省的纵向支持性和辅助性健康服务调查(LISA)。药物使用是一个三级分类变量,结合了酒精依赖史和注射吸毒史的信息,定义为:无酒精和注射吸毒史;有酒精或注射吸毒史;有酒精和注射吸毒史。病毒学反应(pVL)定义为病毒载量下降≥2 log10拷贝/毫升。免疫反应定义为CD4细胞计数百分比增加≥100%。我们使用累积logit模型进行有序反应以实现我们的目标。在537名HIV感染患者中,112名(21%)有酒精和注射吸毒史,173名(32%)不依从(<95%),196名(36%)有CD4⁺/pVL⁺(最佳)反应,180名(34%)有CD4⁺/pVL⁻或CD4⁻/pVL⁺(不完全)反应,161名(30%)有CD4⁻/pVL⁻(最差)反应。对于有酒精和注射吸毒史的个体,估计不依从的概率为0.61,最佳、不完全和最差反应的概率分别为(0.15、0.25、0.60)。对药物依赖的筛查和检测将识别出不依从的高危个体,并理想地防止他们的HIV疾病进展到难以管理的晚期。